Skip to main content

Hyperalgesia

4
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
DuloxetinePhase 1
GW406381Phase 1
Orion
OrionUK - Cambridge
1 program
1
Nitrous OxidePhase 1
Orion Pharma
Orion PharmaUK - Reading
1 program
1
Nitrous OxidePhase 11 trial
Active Trials
NCT01581450Completed20Est. Apr 2012
GSK
GSKLONDON, United Kingdom
1 program
GW406381PHASE_11 trial
Active Trials
NCT00279032Completed40

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Orion PharmaNitrous Oxide
GSKGW406381

Clinical Trials (2)

Total enrollment: 60 patients across 2 trials

Hyperalgesia and Pain

Start: Jan 2012Est. completion: Apr 201220 patients
Phase 1Completed

GW406381 In Patients With Peripheral Nerve Injury

Start: Sep 200340 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.